Two organizations with roots at MIT have joined forces to improve our understanding and use of rapid antigen tests in real-world settings. IDx20, headed by MIT scientist Irene Bosch, together with the Chelsea Project are the recipients of one of only two national research grants totaling $1.8 million from the Reagan-Udall Foundation for the FDA (FDA Foundation) to evaluate the Real-World Performance of In Vitro Diagnostics (PIVD). The project will be executed on the ground by the Chelsea Project, a coalition of teams led by the Center of Complex Interventions, a nonprofit also spun out of MIT.

The full article is available here.